ADEL Y02
Alternative Names: ADEL-Y02Latest Information Update: 09 Oct 2023
At a glance
- Originator ADEL
- Class Antidementias; Monoclonal antibodies
- Mechanism of Action Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Alzheimer's disease
Most Recent Events
- 09 Oct 2023 ADEL Y02 is available for licensing as of 09 Oct 2023. https://www.adelpharm.com/adel-y02
- 20 Sep 2023 Early research in Alzheimer's disease in South Korea (Parenteral), prior to September 2023 (ADEL pipeline, September 2023)